<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14317">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00314145</url>
  </required_header>
  <id_info>
    <org_study_id>H-040-009</org_study_id>
    <nct_id>NCT00314145</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX</brief_title>
  <official_title>A Multicentre, Randomized, Double-blind, Phase III Study of The Comparative Immunogenicity, Safety and Tolerability of Two Japanese Encephalitis Vaccines (ChimeriVax™-JE and JE-VAX®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine non-inferiority in seroconversion and to compare
      the safety and tolerability between ChimeriVaxTM-JE and JE-VAX to the respective homologous
      virus strain after completion of vaccination course.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Participants With Japanese Encephalitis (Homologous Virus) Seroconversion Following Either ChimeriVax™-JE or JE-Vax® Vaccination</measure>
    <time_frame>Up to Day 60 post-first vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antibodies to Japanese encephalitis (JE) were measured by 50% plaque reduction neutralization test (PRNT50). Seroconversion was defined as a titer of ≥ 1:10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Treatment Emergent Local Adverse Events and Treatment Emergent Systemic Reactions Post-Vaccination With Either ChimeriVax™-JE or JE-Vax®</measure>
    <time_frame>Day 0 (Pre-vaccination) up to 60 days post-first vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Treatment emergent local adverse events: Pain, Erythema, Pruritus, Swelling, Induration, and others as reported.
Treatment emergent systemic reactions: Fatigue, Malaise, Chills, Pyrexia, Headache, Myalgia, Arthralgia, Diarrhea, Nausea, Vomiting, and Rash.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutralizing Antibody Geometric Mean Titers (GMTs) to Japanese Encephalitis (Homologous Virus) Following Either ChimeriVax™-JE or JE-Vax® Vaccination</measure>
    <time_frame>Up to Day 60 post-first vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antibodies to Japanese encephalitis (JE) were measured by 50% plaque reduction neutralization test (PRNT50).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in the Japanese Encephalitis (Homologous Virus) Neutralizing Antibody Titer Categories on Day 60 Following Either ChimeriVax™-JE or JE-Vax® Vaccination</measure>
    <time_frame>Day 60 post-first vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antibodies to Japanese encephalitis (JE) were measured by 50% plaque reduction neutralization test (PRNT50).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">820</enrollment>
  <condition>Japanese Encephalitis</condition>
  <arm_group>
    <arm_group_label>ChimeriVax™-JE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received dose each of saline placebo on Days 0 and 7. On Day 30, participants received vaccinations of ChimeriVax™-JE vaccine and saline placebo into different arms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JE-VAX®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 1 dose each of JE-VAX® vaccine on Days 0, 7, and 30, and a dose of saline placebo into a different arm on Day 30.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ChimeriVax™-JE</intervention_name>
    <description>0.5 mL, Subcutaneous (ChimeriVax™-JE); 1.0 mL, (Saline)</description>
    <arm_group_label>ChimeriVax™-JE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>JE-VAX®</intervention_name>
    <description>0.5 mL, Subcutaneous (JE-Vax®); 1.0 mL, (Saline)</description>
    <arm_group_label>JE-VAX®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects aged 18 or above

          -  Subjects in good general health.

          -  Females must have negative pregnancy test and be using adequate form of contraception

        Exclusion Criteria:

          -  History of vaccination/infection with JE or Yellow fever or other flaviviruses

          -  History of residence/travel to flavivirus endemic regions

          -  History of anaphylaxis/serious adverse reactions

          -  Administration of vaccine within 30 days of study or during treatment period

          -  Clinically significant physical exam/medical history/lab abnormalities

          -  Pregnancy

          -  Excessive alcohol/drug abuse

          -  Hypersensitivity to constituents of JE-VAX®

          -  Blood transfusion/treatment with blood product within 6months of study and during
             study treatment period

          -  Known/suspected immunodeficiency

          -  Compromised blood brain barrier

          -  Employees of Clinical Research Organization (CRO)/study site staff

          -  Any other condition which would exclude subject.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Angles, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart of America Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New South Wales</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Queensland</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 4, 2012</lastchanged_date>
  <firstreceived_date>April 11, 2006</firstreceived_date>
  <firstreceived_results_date>November 6, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Encephalitis, Japanese</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled and treated from 07 November 2005 to 15 November 2006 at 5 clinical centers in Australia and 5 clinical centers in the US.</recruitment_details>
      <pre_assignment_details>A total of 820 participants who met all of the inclusion criteria and none of the exclusion criteria were enrolled and vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>JE-VAX®</title>
          <description>All participants received 1 subcutaneous dose each of JE-VAX® vaccine on Days 0, 7, and 30, and a subcutaneous dose of saline placebo into a different arm on Day 30.</description>
        </group>
        <group group_id="P2">
          <title>ChimeriVax™-JE</title>
          <description>All participants received 1 dose each of saline placebo on Days 0 and 7. On Day 30, participants received vaccinations of ChimeriVax™-JE vaccine 4 log10 Plaque-forming unit (PFU) and saline placebo into different arms.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="410"/>
                <participants group_id="P2" count="410"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="389"/>
                <participants group_id="P2" count="381"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>JE-VAX®</title>
          <description>All participants received 1 subcutaneous dose each of JE-VAX® vaccine on Days 0, 7, and 30, and a subcutaneous dose of saline placebo into a different arm on Day 30.</description>
        </group>
        <group group_id="B2">
          <title>ChimeriVax™-JE</title>
          <description>All participants received 1 dose each of saline placebo on Days 0 and 7. On Day 30, participants received vaccinations of ChimeriVax™-JE vaccine 4 log10 Plaque-forming unit (PFU) and saline placebo into different arms.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="410"/>
                <measurement group_id="B2" value="410"/>
                <measurement group_id="B3" value="820"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="410"/>
                <measurement group_id="B2" value="410"/>
                <measurement group_id="B3" value="820"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="37.0" spread="14.81"/>
                <measurement group_id="B2" value="37.7" spread="15.11"/>
                <measurement group_id="B3" value="37.4" spread="14.96"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="205"/>
                <measurement group_id="B2" value="217"/>
                <measurement group_id="B3" value="422"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="205"/>
                <measurement group_id="B2" value="193"/>
                <measurement group_id="B3" value="398"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Australia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="203"/>
                <measurement group_id="B2" value="120"/>
                <measurement group_id="B3" value="323"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="207"/>
                <measurement group_id="B2" value="290"/>
                <measurement group_id="B3" value="497"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Japanese Encephalitis (Homologous Virus) Seroconversion Following Either ChimeriVax™-JE or JE-Vax® Vaccination</title>
        <description>Antibodies to Japanese encephalitis (JE) were measured by 50% plaque reduction neutralization test (PRNT50). Seroconversion was defined as a titer of ≥ 1:10.</description>
        <time_frame>Up to Day 60 post-first vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Seroconversion was assessed in all participants who were seronegative to JE (both Nakayama and ChimeriVax™-JE strains) at baseline and had no protocol violations that would have interfered with evaluation of primary outcomes (Efficacy Population).</population>
        <group_list>
          <group group_id="O1">
            <title>JE-VAX®</title>
            <description>All participants received 1 subcutaneous dose each of JE-VAX® vaccine on Days 0, 7, and 30, and a subcutaneous dose of saline placebo into a different arm on Day 30.</description>
          </group>
          <group group_id="O2">
            <title>ChimeriVax™-JE</title>
            <description>All participants received 1 subcutaneous dose each of saline placebo on Days 0 and 7. On Day 30, participants received vaccinations of ChimeriVax™-JE vaccine 4 log10 PFU and saline placebo into different arms.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="365"/>
                  <measurement group_id="O2" value="346"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Japanese Encephalitis (Homologous Virus) Seroconversion Following Either ChimeriVax™-JE or JE-Vax® Vaccination</title>
            <description>Antibodies to Japanese encephalitis (JE) were measured by 50% plaque reduction neutralization test (PRNT50). Seroconversion was defined as a titer of ≥ 1:10.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Day 44 (N = 0, 346)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="NA">Seroconversion was not assessed at this time point for this group.</measurement>
                  <measurement group_id="O2" value="324"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 60 (N = 365, 346)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="273"/>
                  <measurement group_id="O2" value="343"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutralizing Antibody Geometric Mean Titers (GMTs) to Japanese Encephalitis (Homologous Virus) Following Either ChimeriVax™-JE or JE-Vax® Vaccination</title>
        <description>Antibodies to Japanese encephalitis (JE) were measured by 50% plaque reduction neutralization test (PRNT50).</description>
        <time_frame>Up to Day 60 post-first vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Geometric mean titers were assessed in all participants who were seronegative to JE (both Nakayama and ChimeriVax™-JE strains) at baseline and had no protocol violations that would have interfered with evaluation of primary outcomes (Efficacy Population).</population>
        <group_list>
          <group group_id="O1">
            <title>JE-VAX®</title>
            <description>All participants received 1 subcutaneous dose each of JE-VAX® vaccine on Days 0, 7, and 30, and a subcutaneous dose of saline placebo into a different arm on Day 30.</description>
          </group>
          <group group_id="O2">
            <title>ChimeriVax™-JE</title>
            <description>All participants received 1 subcutaneous dose each of saline placebo on Days 0 and 7. On Day 30, participants received vaccinations of ChimeriVax™-JE vaccine 4 log10 PFU and saline placebo into different arms.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="365"/>
                  <measurement group_id="O2" value="346"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Neutralizing Antibody Geometric Mean Titers (GMTs) to Japanese Encephalitis (Homologous Virus) Following Either ChimeriVax™-JE or JE-Vax® Vaccination</title>
            <description>Antibodies to Japanese encephalitis (JE) were measured by 50% plaque reduction neutralization test (PRNT50).</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Day 44 (N = 0, 346)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="NA">Geometric mean titers were not assessed at this time point for this group.</measurement>
                  <measurement group_id="O2" value="312.3" lower_limit="255.1" upper_limit="382.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 60 (N = 365, 346)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37.4" lower_limit="32.5" upper_limit="42.9"/>
                  <measurement group_id="O2" value="1391.7" lower_limit="1156.6" upper_limit="1674.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in the Japanese Encephalitis (Homologous Virus) Neutralizing Antibody Titer Categories on Day 60 Following Either ChimeriVax™-JE or JE-Vax® Vaccination</title>
        <description>Antibodies to Japanese encephalitis (JE) were measured by 50% plaque reduction neutralization test (PRNT50).</description>
        <time_frame>Day 60 post-first vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Antibody titers were assessed in all participants who were seronegative to JE (both Nakayama and ChimeriVax™-JE strains) at baseline and had no protocol violations that would have interfered with evaluation of primary outcomes (Efficacy Population).</population>
        <group_list>
          <group group_id="O1">
            <title>JE-VAX®</title>
            <description>All participants received 1 subcutaneous dose each of JE-VAX® vaccine on Days 0, 7, and 30, and a subcutaneous dose of saline placebo into a different arm on Day 30.</description>
          </group>
          <group group_id="O2">
            <title>ChimeriVax™-JE</title>
            <description>All participants received 1 subcutaneous dose each of saline placebo on Days 0 and 7. On Day 30, participants received vaccinations of ChimeriVax™-JE vaccine 4 log10 PFU and saline placebo into different arms.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="365"/>
                  <measurement group_id="O2" value="346"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants in the Japanese Encephalitis (Homologous Virus) Neutralizing Antibody Titer Categories on Day 60 Following Either ChimeriVax™-JE or JE-Vax® Vaccination</title>
            <description>Antibodies to Japanese encephalitis (JE) were measured by 50% plaque reduction neutralization test (PRNT50).</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Titer &lt; 10</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="63"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Titer 10 to &lt; 20</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Titer 20 to &lt; 40</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Titer 40 to &lt; 160</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="151"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Titer 160 to &lt; 640</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="63"/>
                  <measurement group_id="O2" value="76"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Titer 640 to &lt; 2560</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="75"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Titer ≥ 2560</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="170"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Treatment Emergent Local Adverse Events and Treatment Emergent Systemic Reactions Post-Vaccination With Either ChimeriVax™-JE or JE-Vax®</title>
        <description>Treatment emergent local adverse events: Pain, Erythema, Pruritus, Swelling, Induration, and others as reported.
Treatment emergent systemic reactions: Fatigue, Malaise, Chills, Pyrexia, Headache, Myalgia, Arthralgia, Diarrhea, Nausea, Vomiting, and Rash.</description>
        <time_frame>Day 0 (Pre-vaccination) up to 60 days post-first vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treatment emergent local adverse events and systemic reactions were assessed in all subjects who had at least one injection (ChimeriVax™-JE, JE-Vax®, or placebo), according to the treatment actually received (Safety Population).</population>
        <group_list>
          <group group_id="O1">
            <title>JE-VAX®</title>
            <description>All participants received 1 subcutaneous dose each of JE-VAX® vaccine on Days 0, 7, and 30, and a subcutaneous dose of saline placebo into a different arm on Day 30.</description>
          </group>
          <group group_id="O2">
            <title>ChimeriVax™-JE</title>
            <description>All participants received 1 dose each of saline placebo on Days 0 and 7. On Day 30, participants received vaccinations of ChimeriVax™-JE vaccine 4 log10 Plaque-forming unit (PFU) and saline placebo into different arms.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="410"/>
                  <measurement group_id="O2" value="410"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Reporting Treatment Emergent Local Adverse Events and Treatment Emergent Systemic Reactions Post-Vaccination With Either ChimeriVax™-JE or JE-Vax®</title>
            <description>Treatment emergent local adverse events: Pain, Erythema, Pruritus, Swelling, Induration, and others as reported.
Treatment emergent systemic reactions: Fatigue, Malaise, Chills, Pyrexia, Headache, Myalgia, Arthralgia, Diarrhea, Nausea, Vomiting, and Rash.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Injection Site Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="262"/>
                  <measurement group_id="O2" value="105"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection Site Erythema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="123"/>
                  <measurement group_id="O2" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection Site Pruritus</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="107"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection Site Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="85"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection Site Hemorrhage</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection Site Rash</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection Site Edema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection Site Joint Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection Site Reaction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection Site Discomfort</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection Site Joint Movement Impairment</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection Site Warmth</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Venipuncture Site Bruise</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="131"/>
                  <measurement group_id="O2" value="152"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Malaise</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="113"/>
                  <measurement group_id="O2" value="113"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chills</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pyrexia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="190"/>
                  <measurement group_id="O2" value="193"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="107"/>
                  <measurement group_id="O2" value="105"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="58"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="57"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nausea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="56"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rash</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from Day 0 (post-vaccination) through Day 60 post first vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>JE-VAX®</title>
          <description>All participants received 1 subcutaneous dose each of JE-VAX® vaccine on Days 0, 7, and 30, and a subcutaneous dose of saline placebo into a different arm on Day 30.</description>
        </group>
        <group group_id="E2">
          <title>ChimeriVax™-JE</title>
          <description>All participants received 1 dose each of saline placebo on Days 0 and 7. On Day 30, participants received vaccinations of ChimeriVax™-JE vaccine 4 log10 Plaque-forming unit (PFU) and saline placebo into different arms.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 7.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non Cardiac Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple Sclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Parkinson's Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Airways Disease Exacerbated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA 7.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="262" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="193" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="80" subjects_affected="56" subjects_at_risk="410"/>
                <counts group_id="E2" events="99" subjects_affected="57" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="96" subjects_affected="53" subjects_at_risk="410"/>
                <counts group_id="E2" events="75" subjects_affected="56" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="48" subjects_affected="32" subjects_at_risk="410"/>
                <counts group_id="E2" events="68" subjects_affected="43" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="399" subjects_affected="131" subjects_at_risk="410"/>
                <counts group_id="E2" events="366" subjects_affected="152" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="804" subjects_affected="262" subjects_at_risk="410"/>
                <counts group_id="E2" events="207" subjects_affected="105" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" events="256" subjects_affected="123" subjects_at_risk="410"/>
                <counts group_id="E2" events="35" subjects_affected="27" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Injection Site Pruritus</sub_title>
                <counts group_id="E1" events="187" subjects_affected="107" subjects_at_risk="410"/>
                <counts group_id="E2" events="46" subjects_affected="29" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" events="149" subjects_affected="85" subjects_at_risk="410"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="248" subjects_affected="113" subjects_at_risk="410"/>
                <counts group_id="E2" events="224" subjects_affected="113" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="228" subjects_affected="107" subjects_at_risk="410"/>
                <counts group_id="E2" events="192" subjects_affected="105" subjects_at_risk="410"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="99" subjects_affected="58" subjects_at_risk="410"/>
                <counts group_id="E2" events="122" subjects_affected="58" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="546" subjects_affected="190" subjects_at_risk="410"/>
                <counts group_id="E2" events="465" subjects_affected="193" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="36" subjects_affected="26" subjects_at_risk="410"/>
                <counts group_id="E2" events="33" subjects_affected="23" subjects_at_risk="410"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
